Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2014
OPERATING ACTIVITIES      
Net loss $ (25,766,198) $ (15,197,865) $ (9,130,664)
Adjustments to reconcile net loss to net cash used by operating activities:      
Common stock issued for services 1,754,814 635,288  
Warrants issued for services   8,559 1,177,095
Stock option expense 2,913,626 3,579,788 2,074,487
Change in fair value of contingent consideration 1,185,667 (2,637,756)  
Share in losses on investment in joint venture   103,143 10,643
Depreciation 64,632 40,623 17,850
Amortization of intangible assets 1,124,644 1,138,631 448,456
Impairment of intangibles   338,906  
Gain on settlement of accounts payable (710,264) (40,636)  
Changes in operating assets and liabilities      
Prepaid expenses and deposits (64,794) 7,214 105,823
Accounts payable and accrued expenses 3,511,984 1,331,120 (63,822)
Net Cash Used in Operating Activities (15,985,889) (10,692,985) (5,360,132)
INVESTING ACTIVITIES      
Acquisition of SKS Ocular's assets     (3,500,000)
Investment in joint venture   (100,000) (13,786)
Purchase of property and equipment (14,510) (184,951) (1,083)
Net Cash Used in Investing Activities (14,510) (284,951) (3,514,869)
FINANCING ACTIVITIES      
Proceeds for issuance of common stock for cash   26,582,998 16,876,000
Proceeds from warrants exercised for cash 26,041 80,003 260,752
Repayments of short-term notes payable (176,075) (208,236) (164,152)
Net Cash Provided by/(Used in) Financing Activities (150,034) 26,454,765 16,972,600
NET CHANGE IN CASH AND CASH EQUIVALENTS (16,150,433) 15,476,829 8,097,599
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 28,697,323 13,220,494 5,122,895
CASH AND CASH EQUIVALENTS AT END OF PERIOD 12,546,890 28,697,323 13,220,494
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION      
Interest 6,071 5,977 5,576
NON CASH FINANCING ACTIVITIES:      
Settlement of contingent consideration 3,425,270    
Financing of insurance premiums through issuance of short term notes 215,810 212,400 194,000
Subscription receivable from exercise of warrants $ 118,801    
Conversion of preferred for common stock     50
Noncash exercise of options and warrants     223
Common stock issued to acquire intangible assets     10,180,224
Common stock issued to settle accounts payable   $ 50,000 $ 50,000